187 results on '"Wei, Feng"'
Search Results
2. Downregulation of GPX8 in hepatocellular carcinoma: impact on tumor stemness and migration
- Author
-
Tao, Chen-Yang, Wu, Xiao-Ling, Song, Shu-Shu, Tang, Zheng, Zhou, Yu-Fu, Tian, Meng-Xin, Jiang, Xi-Fei, Fang, Yuan, Zhu, Gui-Qi, Huang, Run, Qu, Wei-Feng, Gao, Jun, Chu, Tian-Hao, Yang, Rui, Chen, Jia-Feng, Zhao, Qian-Fu, Ding, Zhen-Bin, Dai, Zhi, Zhou, Jian, Liu, Wei-Ren, Shi, Ying-Hong, and Fan, Jia
- Published
- 2024
- Full Text
- View/download PDF
3. Single center experience with ALPPS and timing with stage 2 in patients with fibrotic/cirrhotic liver
- Author
-
Hung, Kuo-Chen, Wang, Hao-Ping, Li, Wei-Feng, Lin, Yu-Cheng, and Wang, Chih-Chi
- Published
- 2024
- Full Text
- View/download PDF
4. Using the hazard function to evaluate hepatocellular carcinoma recurrence risk after curative resection
- Author
-
Li, Wei-Feng, Moi, Sin-Hua, Liu, Yueh-Wei, Yong, Chee-Chien, Wang, Chih-Chi, Yen, Yi-Hao, and Lin, Chih-Yun
- Published
- 2023
- Full Text
- View/download PDF
5. Effect of early peri-operative arterial lactate concentration level ratios on post-hepatectomy liver failure
- Author
-
Dong-Dong Wang, Meng-Meng Dong, Ya-Ming Xie, Fei-Qi Xu, Tian-Wei Fu, Yu-Chen Wu, Zhe Zhang, Yi Lu, Lei Liang, Wei-Feng Yao, Guo-Liang Shen, Jun-Wei Liu, Cheng-Wu Zhang, Qiu-Ran Xu, and Zun-Qiang Xiao
- Subjects
Arterial lactate ,Hepatocellular carcinoma ,Post-hepatectomy liver failure ,Severe morbidity ,Postoperative haemorrhage ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Post-hepatectomy liver failure (PHLF) is a serious complication after hepatectomy and a major cause of death. The current criteria for PHLF diagnosis (ISGLS consensus) require laboratory data of elevated INR level and hyperbilirubinemia on or after postoperative day 5. This study aims to propose a new indicator for the early clinical prediction of PHLF. Methods The peri-operative arterial lactate concentration level ratios were derived from time points within the 3 days before surgery and within POD1, the patients were divided into two groups: high lactate ratio group (≥ 1) and low lactate ratio group (
- Published
- 2024
- Full Text
- View/download PDF
6. Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation
- Author
-
Qu, Wei-Feng, Tian, Meng-Xin, Lu, Hong-Wei, Zhou, Yu-Fu, Liu, Wei-Ren, Tang, Zheng, Yao, Zhao, Huang, Run, Zhu, Gui-Qi, Jiang, Xi-Fei, Tao, Chen-Yang, Fang, Yuan, Gao, Jun, Wu, Xiao-Ling, Chen, Jia-Feng, Zhao, Qian-Fu, Yang, Rui, Chu, Tian-Hao, Zhou, Jian, Fan, Jia, Yu, Jin-Hua, and Shi, Ying-Hong
- Published
- 2023
- Full Text
- View/download PDF
7. Deciphering intratumoral heterogeneity of hepatocellular carcinoma with microvascular invasion with radiogenomic analysis
- Author
-
Wang, Yi, Zhu, Gui-Qi, Yang, Rui, Wang, Cheng, Qu, Wei-Feng, Chu, Tian-Hao, Tang, Zheng, Yang, Chun, Yang, Li, Zhou, Chang-Wu, Miao, Geng-Yun, Liu, Wei-Ren, Shi, Ying-Hong, and Zeng, Meng-Su
- Published
- 2023
- Full Text
- View/download PDF
8. Radiographic tumor burden score is useful for stratifying the overall survival of hepatocellular carcinoma patients undergoing resection at different Barcelona Clinic Liver Cancer stages
- Author
-
Li, Wei-Feng, Liu, Yueh-Wei, Wang, Chih-Chi, Yong, Chee-Chien, Lin, Chih-Che, and Yen, Yi-Hao
- Published
- 2023
- Full Text
- View/download PDF
9. Overall survival among patients who undergo resection does not differ significantly between T1a and T1b hepatocellular carcinoma based on the 8th American Joint Commission on Cancer
- Author
-
Liu, Yueh-Wei, Li, Wei-Feng, Kuo, Fang-Ying, Eng, Hock-Liew, Wang, Chih-Chi, Lin, Chih-Che, Yong, Chee-Chien, and Yen, Yi-Hao
- Published
- 2023
- Full Text
- View/download PDF
10. Seven centimeters as an optimal cutoff value for prognosis stratification in large monofocal hepatocellular carcinoma
- Author
-
Yen, Yi-Hao, Li, Wei-Feng, Kee, Kwong-Ming, Wang, Chih-Chi, Cheng, Yu-Fan, Lu, Sheng-Nan, Hung, Chao-Hung, Liu, Yueh-Wei, and Hu, Tsung-Hui
- Published
- 2023
- Full Text
- View/download PDF
11. Deciphering intratumoral heterogeneity of hepatocellular carcinoma with microvascular invasion with radiogenomic analysis
- Author
-
Yi Wang, Gui-Qi Zhu, Rui Yang, Cheng Wang, Wei-Feng Qu, Tian-Hao Chu, Zheng Tang, Chun Yang, Li Yang, Chang-Wu Zhou, Geng-Yun Miao, Wei-Ren Liu, Ying-Hong Shi, and Meng-Su Zeng
- Subjects
Hepatocellular carcinoma ,Microvascular invasion ,Radiomics ,Single-cell RNA-seq ,Medicine - Abstract
Abstract Background and aims The recurrence and metastasis of hepatocellular carcinoma (HCC) are mainly caused by microvascular invasion (MVI). Our study aimed to uncover the cellular atlas of MVI+ HCC and investigate the underlying immune infiltration patterns with radiomics features. Methods Three MVI positive HCC and three MVI negative HCC samples were collected for single-cell RNA-seq analysis. 26 MVI positive HCC and 30 MVI negative HCC tissues were underwent bulk RNA-seq analysis. For radiomics analysis, radiomics features score (Radscore) were built using preoperative contrast MRI for MVI prediction and overall survival prediction. We deciphered the metabolism profiles of MVI+ HCC using scMetabolism and scFEA. The correlation of Radscore with the level of APOE+ macrophages and iCAFs was identified. Whole Exome Sequencing (WES) was applied to distinguish intrahepatic metastasis (IM) and multicentric occurrence (MO). Transcriptome profiles were compared between IM and MO. Results Elevated levels of APOE+ macrophages and iCAFs were detected in MVI+ HCC. There was a strong correlation between the infiltration of APOE+ macrophages and iCAFs, as confirmed by immunofluorescent staining. MVI positive tumors exhibited increased lipid metabolism, which was attributed to the increased presence of APOE+ macrophages. APOE+ macrophages and iCAFs were also found in high levels in IM, as opposed to MO. The difference of infiltration level and Radscore between two nodules in IM was relatively small. Furthermore, we developed Radscore for predicting MVI and HCC prognostication that were also able to predict the level of infiltration of APOE+ macrophages and iCAFs. Conclusion This study demonstrated the interactions of cell subpopulations and distinct metabolism profiles in MVI+ HCC. Besides, MVI prediction Radscore and MVI prognostic Radscore were highly correlated with the infiltration of APOE+ macrophages and iCAFs, which helped to understand the biological significance of radiomics and optimize treatment strategy for MVI+ HCC.
- Published
- 2023
- Full Text
- View/download PDF
12. Synthetic miR-26a mimics delivered by tumor exosomes repress hepatocellular carcinoma through downregulating lymphoid enhancer factor 1
- Author
-
Hu, Jie, Liu, Wei-Feng, Zhang, Xiang-Yu, Shi, Guo-Ming, Yang, Xin-Rong, Zhou, Kai-Qian, Hu, Bo, Chen, Fei-Yu, Zhou, Cheng, Lau, Wan-Yee, Fan, Jia, Wang, Zheng, and Zhou, Jian
- Published
- 2023
- Full Text
- View/download PDF
13. Short- and long-term outcomes of laparoscopic versus open liver resection for large hepatocellular carcinoma: a propensity score study
- Author
-
Zhang, Kang-Jun, Liang, Lei, Diao, Yong-Kang, Xie, Ya-Ming, Wang, Dong-Dong, Xu, Fei-Qi, Ye, Tai-Wei, Lu, Wen-Feng, Cheng, Jian, Shen, Guo-Liang, Yao, Wei-Feng, Lu, Yi, Xiao, Zun-Qiang, Zhang, Jun-Gang, Zhang, Cheng-Wu, Huang, Dong-Sheng, and Liu, Jun-Wei
- Published
- 2023
- Full Text
- View/download PDF
14. Effect of early peri-operative arterial lactate concentration level ratios on post-hepatectomy liver failure
- Author
-
Wang, Dong-Dong, Dong, Meng-Meng, Xie, Ya-Ming, Xu, Fei-Qi, Fu, Tian-Wei, Wu, Yu-Chen, Zhang, Zhe, Lu, Yi, Liang, Lei, Yao, Wei-Feng, Shen, Guo-Liang, Liu, Jun-Wei, Zhang, Cheng-Wu, Xu, Qiu-Ran, and Xiao, Zun-Qiang
- Published
- 2024
- Full Text
- View/download PDF
15. Validation of an alpha-fetoprotein model to predict recurrence after liver resection for hepatocellular carcinoma
- Author
-
Li, Wei-Feng, Yen, Yi-Hao, Liu, Yueh-Wei, Wang, Chih-Chi, Yong, Chee-Chien, Lin, Chih-Che, Cheng, Yu-Fan, and Wang, Jing-Houng
- Published
- 2022
- Full Text
- View/download PDF
16. Preoperative predictors of non-transplantable recurrence after resection for early-stage hepatocellular carcinoma: application in an East Asian cohort
- Author
-
Li, Wei-Feng, Yen, Yi-Hao, Liu, Yueh-Wei, Wang, Chih-Chi, Yong, Chee-Chien, and Lin, Chih-Che
- Published
- 2022
- Full Text
- View/download PDF
17. The pre- and postoperative nomograms to predict the textbook outcomes of patients who underwent hepatectomy for hepatocellular carcinoma
- Author
-
Gui-Lin Xie, Lei Liang, Tai-Wei Ye, Fei-Qi Xu, Dong-Dong Wang, Ya-Ming Xie, Kang-Jun Zhang, Tian-Wei Fu, Wei-Feng Yao, Jun-Wei Liu, and Cheng-Wu Zhang
- Subjects
hepatocellular carcinoma ,textbook outcomes ,nomogram ,hepatectomy ,laparoscopic ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and aimsAn increasing number of studies have confirmed that non-textbook outcomes (non-TO) are a risk factor for the long-term outcome of malignant tumors. It is particularly important to identify the predictive factors of non-TO to improve the quality of surgical treatment. We attempted to construct two nomograms for preoperative and postoperative prediction of non-TO after laparoscopic hepatectomy for hepatocellular carcinoma (HCC).MethodsPatients who underwent curative-intent hepatectomy for HCC between 2014 and 2021 at two Chinese hospitals were analyzed. Using univariate and multivariate analyses, the independent predictors of non-TO were identified. The prediction accuracy is accurately measured by the receiver operating characteristic (ROC) curve and calibration curve. ROC curves for the preoperative and postoperative models, Child–Pugh grade, BCLC staging, and 8th TNM staging were compared relative to predictive accuracy for non-TO.ResultsAmong 515 patients, 286 patients (55.5%) did not achieve TO in the entire cohort. Seven and eight independent risk factors were included in the preoperative and postoperative predictive models by multivariate logistic regression analysis, respectively. The areas under the ROC curves for the postoperative and preoperative models, Child–Pugh grade, BCLC staging, and 8th TNM staging in predicting non-TO were 0.762, 0.698, 0.579, 0.569, and 0.567, respectively.ConclusionOur proposed preoperative and postoperative nomogram models were able to identify patients at high risk of non-TO following laparoscopic resection of HCC, which may guide clinicians to make individualized surgical decisions, improve postoperative survival, and plan adjuvant therapy against recurrence.
- Published
- 2023
- Full Text
- View/download PDF
18. The characteristics of patients with macrovascular invasion in hepatocellular carcinoma: when East meets West
- Author
-
Yen, Yi-Hao, Li, Wei-Feng, Kee, Kwong-Ming, Wang, Chih-Chi, Cheng, Yu-Fan, Wang, Jing-Houng, Lu, Sheng-Nan, and Hung, Chao-Hung
- Published
- 2022
- Full Text
- View/download PDF
19. Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study
- Author
-
Gui‐Qi Zhu, Wei‐Ren Liu, Zheng Tang, Wei‐Feng Qu, Yuan Fang, Xi‐Fei Jiang, Shu‐Shu Song, Han Wang, Chen‐Yang Tao, Pei‐Yun Zhou, Run Huang, Jun Gao, Hai‐Xiang Sun, Zhen‐Bin Ding, Yuan‐Fei Peng, Zhi Dai, Jian Zhou, Jia Fan, and Ying‐Hong Shi
- Subjects
biomarker ,ctDNA ,hepatocellular carcinoma ,tumor recurrence ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
We studied the value of circulating tumor DNA (ctDNA) in predicting early postoperative tumor recurrence and monitoring tumor burden in patients with hepatocellular carcinoma (HCC). Plasma‐free DNA, germline DNA, and tissue DNA were isolated from 41 patients with HCC. Serial ctDNAs were analyzed by next‐generation sequencing before and after operation. Whole‐exome sequencing was used to detect the DNA of HCC and adjacent tissues. In total, 47 gene mutations were identified in the ctDNA of the 41 patients analyzed before surgery. ctDNA was detected in 63.4% and 46% of the patient plasma pre‐ and postoperation, respectively. The preoperative ctDNA positivity rate was significantly lower in the nonrecurrence group than in the recurrence group. With a median follow‐up of 17.7 months, nine patients (22%) experienced tumor recurrence. ctDNA positivity at two time‐points was associated with significantly shorter recurrence‐free survival (RFS). Tumors with NRAS, NEF2L2, and MET mutations had significantly shorter times to recurrence than those without mutations and showed high recurrence prediction performance by machine learning. Multivariate analyses showed that the median variant allele frequency (VAF) of mutations in preoperative ctDNA was a strong independent predictor of RFS. ctDNA is a real‐time monitoring indicator that can accurately reflect tumor burden. The median VAF of baseline ctDNA is a strong independent predictor of RFS in individuals with HCC.
- Published
- 2022
- Full Text
- View/download PDF
20. Impact of metabolic syndrome on the long-term prognosis of patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy
- Author
-
Kang-Jun Zhang, Tai-Wei Ye, Wen-Feng Lu, Fei-Qi Xu, Ya-Ming Xie, Dong-Dong Wang, Zun-Qiang Xiao, Si-Yu Liu, Wei-Feng Yao, Jian Cheng, Guo-Liang Shen, Jun-Wei Liu, Cheng-Wu Zhang, Dong-Sheng Huang, and Lei Liang
- Subjects
metabolic syndrome ,hepatitis virus B ,hepatocellular carcinoma ,hepatectomy ,survival ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background & aimsThe long-term prognosis of patients with metabolic syndrome (MS) and hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) after radical hepatectomy remains unclear. The purpose of this study was to elucidate the effect of MS on long-term survival for patients with HBV-related HCC after hepatectomy.MethodsPatients with HBV-HCC after hepatectomy were included. Patients were stratified into MS-HBV-HCC and HBV-HCC groups. Clinical features and surgical outcomes were compared between the two groups, and COX regression analysis was used to determine independent risk factors associated with overall survival (OS) and recurrence-free survival (RFS).Result389 patients (MS-HBV-HCC group: n=50, HBV-HCC group: n=339) were enrolled for further analysis. Baseline characteristics showed that patients with MS-HBV-HCC were associated with a high rate of elderly patients, ASA score, and co-morbid illness, but a lower rate of anatomy hepatectomy. There were no significant differences in perioperative complications. After excluding patients who relapsed or died within 90 days after surgery, multivariate Cox regression analysis showed MS was an independent risk factor of OS (HR 1.68, 95% CI 1.05-2.70, P = 0.032) and RFS (HR 1.78, 95% CI 1.24-2.57, P = 0.002).ConclusionMS is an independent risk factor for poor OS and RFS in HBV-infected HCC patients after radical hepatectomy. This suggests that we need to strengthen postoperative follow-up of the relevant population and encourage patients to develop a healthy lifestyle.
- Published
- 2022
- Full Text
- View/download PDF
21. Exploring pathological signatures for predicting the recurrence of early-stage hepatocellular carcinoma based on deep learning
- Author
-
Wei-Feng Qu, Meng-Xin Tian, Jing-Tao Qiu, Yu-Cheng Guo, Chen-Yang Tao, Wei-Ren Liu, Zheng Tang, Kun Qian, Zhi-Xun Wang, Xiao-Yu Li, Wei-An Hu, Jian Zhou, Jia Fan, Hao Zou, Ying-Yong Hou, and Ying-Hong Shi
- Subjects
hepatocellular carcinoma ,curative resection ,recurrence ,deep learning ,pathological slides ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundPostoperative recurrence impedes the curability of early-stage hepatocellular carcinoma (E-HCC). We aimed to establish a novel recurrence-related pathological prognosticator with artificial intelligence, and investigate the relationship between pathological features and the local immunological microenvironment.MethodsA total of 576 whole-slide images (WSIs) were collected from 547 patients with E-HCC in the Zhongshan cohort, which was randomly divided into a training cohort and a validation cohort. The external validation cohort comprised 147 Tumor Node Metastasis (TNM) stage I patients from The Cancer Genome Atlas (TCGA) database. Six types of HCC tissues were identified by a weakly supervised convolutional neural network. A recurrence-related histological score (HS) was constructed and validated. The correlation between immune microenvironment and HS was evaluated through extensive immunohistochemical data.ResultsThe overall classification accuracy of HCC tissues was 94.17%. The C-indexes of HS in the training, validation and TCGA cohorts were 0.804, 0.739 and 0.708, respectively. Multivariate analysis showed that the HS (HR= 4.05, 95% CI: 3.40-4.84) was an independent predictor for recurrence-free survival. Patients in HS high-risk group had elevated preoperative alpha-fetoprotein levels, poorer tumor differentiation and a higher proportion of microvascular invasion. The immunohistochemistry data linked the HS to local immune cell infiltration. HS was positively correlated with the expression level of peritumoral CD14+ cells (p= 0.013), and negatively with the intratumoral CD8+ cells (p< 0.001).ConclusionsThe study established a novel histological score that predicted short-term and long-term recurrence for E-HCCs using deep learning, which could facilitate clinical decision making in recurrence prediction and management.
- Published
- 2022
- Full Text
- View/download PDF
22. Association of preoperative albumin–bilirubin with surgical textbook outcomes following laparoscopic hepatectomy for hepatocellular carcinoma
- Author
-
Fei-Qi Xu, Tai-Wei Ye, Dong-Dong Wang, Ya-Ming Xie, Kang-Jun Zhang, Jian Cheng, Zun-Qiang Xiao, Si-Yu Liu, Kai Jiang, Wei-Feng Yao, Guo-Liang Shen, Jun-Wei Liu, Cheng-Wu Zhang, Dong-Sheng Huang, and Lei Liang
- Subjects
hepatocellular carcinoma ,hepatectomy ,albumin–bilirubin ,textbook outcomes ,laparoscopic ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background and aimsRecently, the effectiveness of “textbook outcomes (TO)” in the evaluation of surgical quality has been recognized by more and more scholars. This study tended to examine the association between preoperative albumin–bilirubin (ALBI) grades and the incidence of achieving or not achieving TO (non-TO) in patients with hepatocellular carcinoma (HCC) undergoing laparoscopic hepatectomy.MethodsThe patients were stratified into two groups: ALBI grade 1 (ALBI ≤ -2.60) and ALBI grade 2/3 (ALBI > -2.60). The characteristics of patients and the incidence of non-TO were compared. Multivariate analyses were performed to determine whether ALBI grade was independently associated with TO.ResultsIn total, 378 patients were enrolled, including 194 patients (51.3%) in the ALBI grade 1 group and 184 patients (48.7%) in the ALBI grade 2/3 group. In the whole cohort, 198 patients (52.4%) did not achieve TO, and the incidence of non-TO in the ALBI grade 2/3 group was obviously higher than that in the ALBI grade 1 group (n = 112, 60.9% vs. n = 86, 44.3%, P = 0.001). The multivariate analyses showed that ALBI grade 2/3 was an independent risk factor for non-TO (OR: 1.95, 95%CI: 1.30–2.94, P = 0.023).ConclusionsMore than half (52.4%) of the patients with hepatocellular carcinoma did not achieve TO after laparoscopic hepatectomy, and preoperative ALBI grade 2/3 was significantly associated with non-TO. Improving the liver function reserve of patients before operation, thereby reducing the ALBI grade, may increase the probability for patients to reach TO and enable patients to benefit more from surgery.
- Published
- 2022
- Full Text
- View/download PDF
23. Alpha-Fetoprotein Combined with Radiographic Tumor Burden Score to Predict Overall Survival after Liver Resection in Hepatocellular Carcinoma
- Author
-
Yi-Hao Yen, Yueh-Wei Liu, Wei-Feng Li, Chih-Chi Wang, Chee-Chien Yong, Chih-Che Lin, and Chih-Yun Lin
- Subjects
tumor burden score ,hepatocellular carcinoma ,alpha-fetoprotein ,liver resection ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
We evaluated whether combining the radiographic tumor burden score (TBS) and alpha-fetoprotein (AFP) level could be used to stratify overall survival (OS) among hepatocellular carcinoma (HCC) patients after liver resection (LR). Patients who underwent LR for Barcelona Clinic Liver Cancer stage 0, A, or B HCC between 2011 and 2018 were enrolled. TBS scores were calculated using the following equation: TBS2 = (largest tumor size (in cm))2 + (tumor number)2. Among 743 patients, 193 (26.0%) patients had a low TBS (7.9). Those with a TBS ≤ 7.9 and AFP < 400 ng/mL had a significantly better OS than those with a TBS > 7.9 and an AFP < 400 ng/mL (p = 0.003) or ≥ 400 ng/mL (p < 0.001). A multivariate analysis using TBS ≤ 7.9 and AFP < 400 ng/mL as the reference values showed that a TBS > 7.9 and an AFP < 400 ng/mL (hazard ratio (HR): 2.063; 95% confidence interval [CI]: 1.175–3.623; p = 0.012) or ≥ 400 ng/mL (HR: 6.570; 95% CI: 3.684–11.719; p < 0.001) were independent predictors of OS. In conclusion, combining radiographic TBSs and AFP levels could stratify OS among HCC patients undergoing LR.
- Published
- 2023
- Full Text
- View/download PDF
24. Stationary Trend in Elevated Serum Alpha-Fetoprotein Level in Hepatocellular Carcinoma Patients
- Author
-
Yi-Hao Yen, Kwong-Ming Kee, Wei-Feng Li, Yueh-Wei Liu, Chih-Chi Wang, Tsung-Hui Hu, Ming-Chao Tsai, and Chih-Yun Lin
- Subjects
alpha-fetoprotein ,hepatocellular carcinoma ,hepatitis B virus ,hepatitis C virus ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
A recent study from the US showed a decreasing trend in the elevated serum alpha-fetoprotein (AFP) level (i.e., ≥20 ng/mL) in hepatocellular carcinoma (HCC) patients at the time of diagnosis. Furthermore, advanced tumor stage and severe underlying liver disease were associated with elevated AFP levels. We aimed to evaluate this issue in an area endemic for hepatitis B virus (HBV). Between 2011 and 2020, 4031 patients were newly diagnosed with HCC at our institution. After excluding 54 patients with unknown AFP data, the remaining 3977 patients were enrolled in this study. Elevated AFP level was defined as ≥20 ng/mL. Overall, 51.2% of HCC patients had elevated AFP levels; this proportion remained stationary between 2011 and 2020 (51.8% vs. 51.1%). Multivariate analysis showed that female gender (odds ratio (OR) = 1.462; p < 0.001), tumor size per 10 mm increase (OR = 1.155; p < 0.001), multiple tumors (OR = 1.406; p < 0.001), Barcelona Clinic Liver Cancer stages B–D (OR = 1.247; p = 0.019), cirrhosis (OR = 1.288; p = 0.02), total bilirubin > 1.4 mg/dL (OR = 1.218; p = 0.030), and HBV- or hepatitis C virus (HCV)-positive status (OR = 1.720; p < 0.001) were associated with elevated AFP levels. In conclusion, a stationary trend in elevated serum AFP level in HCC patients has been noted in the past 10 years. Advanced tumor stage, severe underlying liver disease, viral etiology, and female gender are associated with elevated AFP levels in HCC patients.
- Published
- 2023
- Full Text
- View/download PDF
25. Molecular Characteristics of T Cell-Mediated Tumor Killing in Hepatocellular Carcinoma
- Author
-
Wei-feng Hong, Mou-yuan Liu, Li Liang, Yang Zhang, Zong-juan Li, Keqi Han, Shi-suo Du, Yan-jie Chen, and Li-heng Ma
- Subjects
hepatocellular carcinoma ,T cell-mediated tumor killing ,tumor microenvironment ,glycolipid metabolism ,somatic mutation analysis ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundAlthough checkpoint blockade is a promising approach for the treatment of hepatocellular carcinoma (HCC), subsets of patients expected to show a response have not been established. As T cell-mediated tumor killing (TTK) is the fundamental principle of immune checkpoint inhibitor therapy, we established subtypes based on genes related to the sensitivity to TKK and evaluated their prognostic value for HCC immunotherapies.MethodsGenes regulating the sensitivity of tumor cells to T cell-mediated killing (referred to as GSTTKs) showing differential expression in HCC and correlations with prognosis were identified by high-throughput screening assays. Unsupervised clustering was applied to classify patients with HCC into subtypes based on the GSTTKs. The tumor microenvironment, metabolic properties, and genetic variation were compared among the subgroups. A scoring algorithm based on the prognostic GSTTKs, referred to as the TCscore, was developed, and its clinical and predictive value for the response to immunotherapy were evaluated.ResultsIn total, 18 out of 641 GSTTKs simultaneously showed differential expression in HCC and were correlated with prognosis. Based on the 18 GSTTKs, patients were clustered into two subgroups, which reflected distinct TTK patterns in HCC. Tumor-infiltrating immune cells, immune-related gene expression, glycolipid metabolism, somatic mutations, and signaling pathways differed between the two subgroups. The TCscore effectively distinguished between populations with different responses to chemotherapeutics or immunotherapy and overall survival.ConclusionsTTK patterns played a nonnegligible role in formation of TME diversity and metabolic complexity. Evaluating the TTK patterns of individual tumor will contribute to enhancing our cognition of TME characterization, reflects differences in the functionality of T cells in HCC and guiding more effective therapy strategies.
- Published
- 2022
- Full Text
- View/download PDF
26. Comparisons of Viral Etiology and Outcomes of Hepatocellular Carcinoma Undergoing Liver Resection between Taiwan and Vietnam
- Author
-
Song-Huy Nguyen-Dinh, Wei-Feng Li, Yueh-Wei Liu, Chih-Chi Wang, Yen-Hao Chen, Jing-Houng Wang, and Chao-Hung Hung
- Subjects
hepatocellular carcinoma ,hepatitis B virus ,hepatitis C virus ,recurrence ,survival ,Microbiology ,QR1-502 - Abstract
Epidemiologic data have suggested that etiologic variations of hepatocellular carcinoma (HCC) exist in different geographic areas, and might be associated with different outcomes. We compared the viral etiology, clinicopathological characteristics and surgical outcomes between 706 Taiwanese and 1704 Vietnamese patients with HCC undergoing liver resection. Vietnamese patients had a significantly higher ratio of hepatitis B virus (HBV) (p < 0.001) and a lower ratio of hepatitis C virus (HCV) (p < 0.001) and non-B non-C than Taiwanese patients. Among patients with HBV or non-B non-C, the mean age was younger in Vietnam than in Taiwan (p < 0.001, p = 0.001, respectively). The HCC patients in Vietnam had significantly higher serum alpha-fetoprotein (AFP) levels (p < 0.001), larger tumors (p < 0.001), and a higher ratio of macrovascular invasion (p < 0.001) and extrahepatic metastasis (p < 0.001), compared to those in Taiwan. Patients treated in Vietnam had a higher tumor recurrent rate (p < 0.001), but no difference in overall survival was found between both groups. In subgroup analysis, the recurrent rate of HCC was the highest in patients with dual HBV/HCV, followed by HCV or HBV, and non-B non-C (p < 0.001). In conclusion, although the viral etiology and clinicopathological characteristics of HCC differed, postoperative overall survival was comparable between patients in Taiwan and Vietnam.
- Published
- 2022
- Full Text
- View/download PDF
27. Hepatitis B virus-related hepatocellular carcinoma has superior overall survival compared with other etiologies.
- Author
-
Yen, Yi-Hao, Kee, Kwong-Ming, Hu, Tsung-Hui, Tsai, Ming-Chao, Kuo, Yuan-Hung, Li, Wei-Feng, Liu, Yueh-Wei, Wang, Chih-Chi, and Lin, Chih-Yun
- Subjects
HEPATITIS B virus ,HEPATITIS B ,ALCOHOLISM ,HEPATOCELLULAR carcinoma ,LIVER disease etiology ,OVERALL survival - Abstract
Background: Whether the etiology of chronic liver disease (CLD) impacts the overall survival (OS) of patients with hepatocellular carcinoma (HCC) remains unclear. We aim to clarify this issue. Materials and methods: Between 2011 and 2020, 3941 patients who were newly diagnosed with HCC at our institution were enrolled in this study. In patients with multiple CLD etiologies, etiology was classified using the following hierarchy: hepatitis C virus (HCV) > hepatitis B virus (HBV) > alcohol-related > all negative. All negative was defined as negative for HCV, HBV, and alcohol use disorder. Results: Among 3941 patients, 1407 patients were classified with HCV-related HCC, 1677 patients had HBV-related HCC, 145 patients had alcohol-related HCC, and 712 patients had all-negative HCC. Using the all-negative group as the reference group, multivariate analysis showed that HBV is an independent predictor of mortality (hazard ratio: 0.856; 95% confidence interval: 0.745–0.983; p = 0.027). Patients with HBV-related HCC had superior OS compared with patients with other CLD etiologies (p<0.001). Subgroup analyses were performed, for Barcelona Clinic Liver Cancer (BCLC) stages 0–A (p<0.001); serum alpha-fetoprotein (AFP) levels≧20 ng/ml (p<0.001); AFP levels < 20 ng/ml (p<0.001); age > 65 years (p<0.001); and the use of curative treatments (p = 0.002). No significant difference in OS between HBV and other etiologies was observed among patients aged ≤ 65 years (p = 0.304); with BCLC stages B–D (p = 0.973); or who underwent non-curative treatments (p = 0.1). Conclusion: Patients with HBV-related HCC had superior OS than patients with other HCC etiologies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Distant survival for patients undergoing surgery using volatile versus IV anesthesia for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study
- Author
-
Xiao-Yan Meng, Xiu-Ping Zhang, Zhe Sun, Hong-Qian Wang, and Wei-Feng Yu
- Subjects
Hepatocellular carcinoma ,Portal vein tumor Thrombus ,Volatile inhalational anesthesia ,Total IV anesthesia ,Anesthesiology ,RD78.3-87.3 - Abstract
Abstract Background Whether anesthesia type is associated with the surgical outcome of Hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) remains to be determined. This study aims to investigate the impact of volatile inhalational anesthesia (INHA) versus total IV anesthesia (TIVA) on the survival outcomes in HCC patients with PVTT. Methods A cohort of in-patients whom were diagnosed of HCC with PVTT in Eastern Hepatobiliary Surgery Hospital, Shanghai, China, from January 1, 2008 to December 24, 2012 were identified. Surgical patients receiving the INHA and TIVA were screened out. The overall survival (OS), recurrence-free survival (RFS) and several postoperative adverse events were compared according to anesthesia types. Results A total of 1513 patients were included in this study. After exclusions are applied, 263 patients remain in the INHA group and 208 in the TIVA group. Patients receiving INHA have a lower 5-year overall survival rate than that of patients receiving TIVA [12.6% (95% CI, 9.0 to 17.3) vs. 17.7% (95% CI, 11.3 to 20.8), P = 0.024]. Results of multivariable Cox-regression analysis also identify that INHA anesthesia is significantly associated with mortality and cancer recurrence after surgery compare to TIVA, with HR (95%CI) of 1.303 (1.065, 1.595) and 1.265 (1.040, 1.539), respectively. Subgroup analysis suggested that in more severe cancer patients, the worse outcome related to INHA might be more significant. Conclusion This retrospective analysis identifies that TIVA is associated with better outcomes compared with INHA. Future prospective studies clinical and translational studies are required to verify this difference and investigate underlying pathophysiology.
- Published
- 2020
- Full Text
- View/download PDF
29. Preoperative Prognostic Nutritional Index and Neutrophil-to-Lymphocyte Ratio Predict Survival Outcomes of Patients With Hepatocellular Carcinoma After Curative Resection
- Author
-
Zhen Qu, Yun-jie Lu, Jia-Wei Feng, Yu-xiang Chen, Long-qing Shi, Jing Chen, Navin Rambaran, Yun-Fei Duan, and Xiao-zhou He
- Subjects
hepatocellular carcinoma ,prognostic nutrition index ,neutrophil-to-lymphocyte ratio ,survival ,prognostic factors ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Increasing evidence indicates that preoperative prognostic indices can serve as independent predictors of survival in patients with cancer. However, the applicability of these indices in patients with hepatocellular carcinoma (HCC) is controversial. This study aims to investigate the prognostic value of these indices in patients with HCC after curative hepatectomy. We retrospectively analyzed the data of 215 patients who underwent curative resection for HCC. Prognostic indices including prognostic nutritional index (PNI) and neutrophil-to-lymphocyte ratio (NLR) were evaluated by comparing by the area under the curve (AUC). Univariate analysis and multivariate analysis were performed to identify independent prognostic factors. Additionally, risk factors were combined to predict the survival of patients. We found that serum albumin concentration, tumor diameter, tumor stage, degree of differentiation, PNI, and NLR were independent prognostic factors for overall survival (OS). Vascular invasion, tumor stage, degree of differentiation, and PNI were independent prognostic factors for recurrence-free survival (RFS). The cutoff value of the PNI and NLR was 43.75 and 3.29, respectively. Patients with low NLR and high PNI had the best outcomes, potentially indicative of the intensive antitumor effects of the immune system. Moreover, patients with at least three risk factors had a significantly lower OS and RFS compared with those with two or fewer risk factors. This new nomogram based on PNI and NLR may provide an accessible and individualized prediction of survival and recurrence for HCC patients.
- Published
- 2022
- Full Text
- View/download PDF
30. Human diet‐derived polyphenolic compounds and hepatic diseases: From therapeutic mechanisms to clinical utilization.
- Author
-
Hu, Qichao, Zhang, Wenwen, Wei, Feng, Huang, Meilan, Shu, Mengyao, Song, Dan, Wen, Jianxia, Wang, Jundong, Nian, Qing, Ma, Xiao, Zeng, Jinhao, and Zhao, Yanling
- Abstract
This review focuses on the potential ameliorative effects of polyphenolic compounds derived from human diet on hepatic diseases. It discusses the molecular mechanisms and recent advancements in clinical applications. Edible polyphenols have been found to play a therapeutic role, particularly in liver injury, liver fibrosis, NAFLD/NASH, and HCC. In the regulation of liver injury, polyphenols exhibit anti‐inflammatory and antioxidant effects, primarily targeting the TGF‐β, NF‐κB/TLR4, PI3K/AKT, and Nrf2/HO‐1 signaling pathways. In the regulation of liver fibrosis, polyphenolic compounds effectively reverse the fibrotic process by inhibiting the activation of hepatic stellate cells (HSC). Furthermore, polyphenolic compounds show efficacy against NAFLD/NASH by inhibiting lipid oxidation and accumulation, mediated through the AMPK, SIRT, and PPARγ pathways. Moreover, several polyphenolic compounds exhibit anti‐HCC activity by suppressing tumor cell proliferation and metastasis. This inhibition primarily involves blocking Akt and Wnt signaling, as well as inhibiting the epithelial‐mesenchymal transition (EMT). Additionally, clinical trials and nutritional evidence support the notion that certain polyphenols can improve liver disease and associated metabolic disorders. However, further fundamental research and clinical trials are warranted to validate the efficacy of dietary polyphenols. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Single-cell and spatial architecture of primary liver cancer.
- Author
-
Zhou, Pei-Yun, Zhou, Cheng, Gan, Wei, Tang, Zheng, Sun, Bao-Ye, Huang, Jin-Long, Liu, Gao, Liu, Wei-Ren, Tian, Meng-Xin, Jiang, Xi-Fei, Wang, Han, Tao, Chen-Yang, Fang, Yuan, Qu, Wei-Feng, Huang, Run, Zhu, Gui-Qi, Huang, Cheng, Fu, Xiu-Tao, Ding, Zhen-Bin, and Gao, Qiang
- Subjects
LIVER cancer ,HEPATOCELLULAR carcinoma ,RNA sequencing ,ENDOTHELIAL cells ,MULTIOMICS ,T cells - Abstract
Primary liver cancer (PLC) poses a leading threat to human health, and its treatment options are limited. Meanwhile, the investigation of homogeneity and heterogeneity among PLCs remains challenging. Here, using single-cell RNA sequencing, spatial transcriptomic and bulk multi-omics, we elaborated a molecular architecture of 3 PLC types, namely hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular-cholangiocarcinoma (CHC). Taking a high-resolution perspective, our observations revealed that CHC cells exhibit internally discordant phenotypes, whereas ICC and HCC exhibit distinct tumor-specific features. Specifically, ICC was found to be the primary source of cancer-associated fibroblasts, while HCC exhibited disrupted metabolism and greater individual heterogeneity of T cells. We further revealed a diversity of intermediate-state cells residing in the tumor-peritumor junctional zone, including a congregation of CPE
+ intermediate-state endothelial cells (ECs), which harbored the molecular characteristics of tumor-associated ECs and normal ECs. This architecture offers insights into molecular characteristics of PLC microenvironment, and hints that the tumor-peritumor junctional zone could serve as a targeted region for precise therapeutical strategies. A comprehensive multi-omic, single-cell, and spatial analysis provides further insight into the major cell types present in three types of primary liver cancer. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
32. Tumor necrosis as a predictor of early tumor recurrence after resection in patients with hepatoma.
- Author
-
Yen, Yi-Hao, Kuo, Fang-Ying, Eng, Hock-Liew, Liu, Yueh-Wei, Yong, Chee-Chien, Li, Wei-Feng, Wang, Chih-Chi, and Lin, Chih-Yun
- Subjects
DISEASE relapse ,SURVIVAL analysis (Biometry) ,NECROSIS ,HEPATOCELLULAR carcinoma ,DISEASE risk factors ,MULTIPLE tumors ,PROGRESSION-free survival - Abstract
Background: Tumor necrosis is a significant risk factor affecting patients' prognosis after liver resection (LR) for hepatocellular carcinoma (HCC). We aimed to develop a model with tumor necrosis as a variable to predict early tumor recurrence in HCC patients undergoing LR. Materials and methods: Patients who underwent LR between 2010 and 2018 for newly diagnosed HCC but did not receive neoadjuvant therapy were enrolled in this retrospective study. Six predictive factors based on pathological features—tumor size > 5 cm, multiple tumors, high-grade tumor differentiation, tumor necrosis, microvascular invasion, and cirrhosis—were chosen a priori based on clinical relevance to construct a multivariate logistic regression model. The variables were always retained in the model. The impact of each variable on early tumor recurrence within one year of LR was estimated and visualized using a nomogram. The nomogram's performance was evaluated using calibration plots with bootstrapping. Results: Early tumor recurrence was observed in 161 (21.3%) patients. The concordance index of the proposed nomogram was 0.722. The calibration plots showed good agreement between nomogram predictions and actual observations of early recurrence. Conclusion: We developed a nomogram incorporating tumor necrosis to predict early recurrence of HCC after LR. Its predictive accuracy is satisfactory. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. A simple preoperative model to predict overall survival of patients undergoing liver resection for hepatocellular carcinoma ≥10 cm.
- Author
-
Yen, Yi-Hao, Li, Wei-Feng, Liu, Yueh-Wei, Yong, Chee-Chien, Wang, Chih-Chi, and Lin, Chih-Yun
- Subjects
- *
OVERALL survival , *HEPATOCELLULAR carcinoma , *KAPLAN-Meier estimator , *MULTIVARIATE analysis , *LIVER - Abstract
Studies have rarely reported on preoperative predictors of prognosis of patients undergoing liver resection (LR) for HCC ≥10 cm. We developed a simple model to predict overall survival (OS) of these patients. We enrolled 305 patients with HCC ≥10 cm undergoing LR. Cirrhosis and imaging-defined AJCC stage were used to develop a preoperative model. Patients were divided into three groups based on the Kaplan–Meier estimator. Group 1 included patients with AJCC stage 1 and no cirrhosis (n = 86), group 2 those with AJCC stage 1 and cirrhosis plus those with AJCC stage 2 or 3 and no cirrhosis (n = 166), and group 3 those with AJCC stage 2 or 3 and cirrhosis (n = 51). The five-year OS of group 1, 2, and 3 was 55%, 32%, and 25%, respectively (p < 0.001). With group 1 as the reference, multivariate analysis of OS showed that group 2 (HR = 2.043; 95% CI = 1.332–3.134; p = 0.001) and group 3 (HR = 2.740; 95% CI = 1.645–4.564; p < 0.001) were independent predictors of OS. We developed a simple model to predict OS of patients undergoing LR for HCC ≥10 cm. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma
- Author
-
Meng-Xin Tian, Wei-Ren Liu, Han Wang, Yu-Fu Zhou, Lei Jin, Xi-Fei Jiang, Chen-Yang Tao, Zheng Tang, Pei-Yun Zhou, Yuan Fang, Wei-Feng Qu, Zhen-Bin Ding, Yuan-Fei Peng, Zhi Dai, Shuang-Jian Qiu, Jian Zhou, Wan Yee Lau, Jia Fan, and Ying-Hong Shi
- Subjects
Hepatocellular carcinoma ,Survival prediction ,Immune signature ,Prognosis ,Medicine - Abstract
Abstract Background Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/intermediate HCC. Methods Twenty-eight immune features were immunohistochemically examined on 352 HCC specimens. The LASSO Cox regression model was used to construct a five-feature-based TRIS. The univariate and multivariate Cox analyses were performed. Based on independent predictors, the immune-clinical prognostic index (ICPI) was established. Performance assessment was measured with C-index and compared with seven traditional staging systems. The independent validation cohort (n = 393) was included to validate the model. Results By using the LASSO method, the TRIS were constructed on the basis of five immune features, CD3intratumoral (T), CD27T, CD68peritumoral (P), CD103T, and PD1T. Multivariate Cox analysis showed that the TRIS was an independent prognostic predictor. In the training cohort, γ-glutamyl transferase, tumor diameter, tumor differentiation, and TRIS were incorporated into the ICPI. The ICPI presented satisfactory discrimination ability, with C-index values of 0.691 and 0.686 in the training and validation cohorts, respectively. Compared with seven conventional staging systems (C-index, training cohort, 0.548–0.597; validation cohort, 0.519–0.610), the ICPI exhibited better performance for early/intermediate-stage HCCs. Further, the patients were categorized into three subgroups with X-tile software, and the stratified ICPI presented a superior corrected Akaike information criterion and homogeneity in both cohorts. Conclusions Our ICPI was a useful and reliable prognostic tool which may offer good individualized prediction capability for HCC patients with early/intermediate stage.
- Published
- 2019
- Full Text
- View/download PDF
35. Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
- Author
-
Yen-Yang Chen, Chih-Chi Wang, Yueh-Wei Liu, Wei-Feng Li, and Yen-Hao Chen
- Subjects
Lenvatinib ,Hepatocellular carcinoma ,Sorafenib ,Survival ,Medicine ,Biology (General) ,QH301-705.5 - Abstract
Background Lenvatinib has been approved for use in the systemic treatment for unresectable hepatocellular carcinoma (HCC). This study aimed to investigate the efficacy and safety of lenvatinib in patients with unresectable HCC who received sorafenib. Methods A total of 40 patients who received lenvatinib after sorafenib were retrospectively identified: as second line in 20 patients, third line in 10 patients, and fourth line and later lines in 10 patients. The treatment response to lenvatinib was determined in accordance with the guidelines of the modified Response Evaluation Criteria in Solid Tumors (mRECIST) every 2–3 months after commencement of lenvatinib. Results Median progression-free survival (PFS) and median overall survival (OS) of the whole population were 3.3 and 9.8 months, respectively. The objective response rate was 27.5%. Univariate and multivariate analyses showed that alpha-fetoprotein level >400 ng/mL was an independent prognostic factor of worse PFS and OS. The clinical outcomes of lenvatinib therapy as second-line, third-line, or fourth line and later line treatment were similar, and previous response to sorafenib could predict the response to subsequent lenvatinib. Most adverse events were grades 1–2, and the majority of patients tolerated the side effects. Our study confirms the efficacy and safety of lenvatinib as second-line and later line treatment for patients with unresectable HCC who received sorafenib in clinical practice.
- Published
- 2020
- Full Text
- View/download PDF
36. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
- Author
-
Jing-Houng Wang, Yen-Yang Chen, Kwong-Ming Kee, Chih-Chi Wang, Ming-Chao Tsai, Yuan-Hung Kuo, Chao-Hung Hung, Wei-Feng Li, Hsiang-Lan Lai, and Yen-Hao Chen
- Subjects
atezolizumab ,bevacizumab ,hepatocellular carcinoma ,neutrophil-to-lymphocyte ratio ,platelet-to-lymphocyte ratio ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Atezolizumab plus bevacizumab has been approved as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma (uHCC). This study was designed to assess the clinical impact of atezolizumab plus bevacizumab in uHCC patients. A total of 48 uHCC patients receiving atezolizumab plus bevacizumab were identified, including first-line, second-line, third-line, and later-line settings. In these patients, the median progression-free survival (PFS) was 5.0 months, including 5.0 months for the first-line treatment, not reached for the second-line treatment, and 2.5 months for the third line and later line treatment. The objective response rate and disease control rate to atezolizumab plus bevacizumab were 27.1% and 68.8%, respectively. The severity of most adverse events was predominantly grade 1–2, and most patients tolerated the toxicities. The ratios of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte (PLR) were used to predict PFS in these patients. The optimal cutoff values of NLR and PLR were 3 and 230, and NLR and PLR were independent prognostic factors for superior PFS in the univariate and multivariate analyses. Our study confirms the efficacy and safety of atezolizumab plus bevacizumab in uHCC patients in clinical practice and demonstrates the prognostic role of NLR and PLR for PFS in these patients.
- Published
- 2022
- Full Text
- View/download PDF
37. Distant survival for patients undergoing surgery using volatile versus IV anesthesia for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study
- Author
-
Meng, Xiao-Yan, Zhang, Xiu-Ping, Sun, Zhe, Wang, Hong-Qian, and Yu, Wei-Feng
- Published
- 2020
- Full Text
- View/download PDF
38. Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study
- Author
-
Yen-Yang Chen, Chao-Long Chen, Chih-Che Lin, Chih-Chi Wang, Yueh-Wei Liu, Wei-Feng Li, and Yen-Hao Chen
- Subjects
lenvatinib ,hepatocellular carcinoma ,liver transplantation ,survival ,safety ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Tumor recurrence is the most common cause of death in hepatocellular carcinoma (HCC) patients who received liver transplantation (LT). Recently, lenvatinib was approved for the systemic treatment of unresectable HCC patients; however, the role of lenvatinib in HCC patients after LT remains unclear. There were 56 patients with recurrent HCC after LT from 2008 to 2018 in our institute, and 10 patients who received lenvatinib were identified. Additionally, to understand the difference in the clinical impact of lenvatinib in the LT and non-LT settings, 25 HCC patients without LT who underwent lenvatinib treatment were identified from our HCC database and regarded as the control group. In the LT group, partial response was 20% and stable disease was 50%, resulting in a disease control rate of 70%; the median progression-free survival (PFS), time to treatment failure (TTF) and overall survival (OS) were 3.7, 3.6 and 16.4 months, respectively. Adverse events (AEs) were predominantly grade 1–2 in severity, and the majority of patients tolerated the side effects. There was no significant difference in PFS/OS, and we observed a similar pattern of AEs between these two groups. Our study confirms the comparable efficacy and safety of lenvatinib in HCC patients with LT and non-LT in clinical practice.
- Published
- 2021
- Full Text
- View/download PDF
39. A preoperative model for predicting early recurrence in patients undergoing resection for single hepatocellular carcinoma.
- Author
-
Liu, Yueh-Wei, Moi, Sin-Hua, Li, Wei-Feng, Lin, Chih-Che, Yong, Chee-Chien, Wang, Chih-Chi, Yen, Yi-Hao, and Lin, Chih-Yun
- Subjects
HEPATOCELLULAR carcinoma ,DISEASE relapse ,LIVER cancer ,REGRESSION analysis ,LIVER diseases - Abstract
The updated Barcelona Clinic Liver Cancer guidelines recommend liver resection (LR) for patients with single hepatocellular carcinoma (HCC) of any size. This study developed a preoperative model for predicting early recurrence in patients undergoing LR for single HCC. We identified 773 patients undergoing LR for single HCC between 2011 and 2017 from the cancer registry database of our institution. Multivariate Cox regression analyses were performed to construct a preoperative model for predicting early recurrence, i.e., recurrence within 2 years of LR. Early recurrence was identified in 219 patients (28.3%). The final model of early recurrence included four predictive factors—alpha-fetoprotein level of ≥20 ng/mL, tumor size of >30 mm, Model for End-Stage Liver Disease score of >8, and cirrhosis. Preoperative application of this model provided three risk strata for recurrence-free survival (RFS): low risk, with 2-year RFS of 79.8% (95% confidence interval [CI]: 75.7–84.2%); intermediate risk, with 2-year RFS of 66.6% (95% CI: 61.1–72.6%); and high risk, with 2-year RFS of 51.1% (95% CI: 43.0–60.8%). We developed a preoperative model for predicting early recurrence after LR for single HCC. This model provides useful information for clinical decision-making. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. The characteristics of patients with macrovascular invasion in hepatocellular carcinoma: when East meets West
- Author
-
Sheng-Nan Lu, Yu-Fan Cheng, Wei-Feng Li, Kwong-Ming Kee, Yi-Hao Yen, Chih-Chi Wang, Jing-Houng Wang, and Chao-Hung Hung
- Subjects
medicine.medical_specialty ,Carcinoma, Hepatocellular ,business.industry ,Liver Neoplasms ,Retrospective cohort study ,Prognosis ,medicine.disease ,Inferior vena cava ,Gastroenterology ,BCLC Stage ,medicine.vein ,Hepatocellular carcinoma ,Internal medicine ,Humans ,Medicine ,Main portal vein ,Surgery ,In patient ,Stage (cooking) ,business ,Liver cancer ,Neoplasm Staging ,Retrospective Studies - Abstract
PURPOSE To evaluate the prevalence and extension of macrovascular invasion (MaVI) in a large cohort of hepatocellular carcinoma (HCC) patients and analyze the association between MaVI and overall survival (OS). METHODS From 2011 to 2018, 2540 patients with newly diagnosed HCC who were managed in our institution were enrolled in this retrospective study. Tumor invasion of the intrahepatic branches of the portal or hepatic veins was defined as peripheral MaVI. Tumor invasion of the main portal vein or inferior vena cava was defined as central MaVI. RESULTS MaVI prevalence was 16.2% (n = 411). Among patients with Barcelona Clinic Liver Cancer (BCLC) stage C and Child-Pugh class A, 165 patients presented with peripheral MaVI and 89 patients with central MaVI. The median OS was 13.2 months (95% confidence interval [CI]: 11.4-15.4) in the peripheral MaVI group and 6.6 months (95% CI: 3.6-9.5) in the central MaVI group (p
- Published
- 2021
41. Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma
- Author
-
Tian, Meng-Xin, Liu, Wei-Ren, Wang, Han, Zhou, Yu-Fu, Jin, Lei, Jiang, Xi-Fei, Tao, Chen-Yang, Tang, Zheng, Zhou, Pei-Yun, Fang, Yuan, Qu, Wei-Feng, Ding, Zhen-Bin, Peng, Yuan-Fei, Dai, Zhi, Qiu, Shuang-Jian, Zhou, Jian, Lau, Wan Yee, Fan, Jia, and Shi, Ying-Hong
- Published
- 2019
- Full Text
- View/download PDF
42. Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study
- Author
-
Wei-Ren Liu, Run Huang, Zhi Dai, Gui-Qi Zhu, Han Wang, Wei-Feng Qu, Zhen-Bin Ding, Xi-Fei Jiang, Yuan-Fei Peng, Yuan Fang, Hai-Xiang Sun, Jun Gao, Zheng Tang, Jia Fan, Ying-Hong Shi, Shushu Song, Pei-Yun Zhou, Chen-Yang Tao, and Jian Zhou
- Subjects
Male ,Neuroblastoma RAS viral oncogene homolog ,Oncology ,Cancer Research ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Gene mutation ,Germline ,Circulating Tumor DNA ,Gene Frequency ,Internal medicine ,Genetics ,Humans ,Medicine ,In patient ,Prospective Studies ,Prospective cohort study ,RC254-282 ,Research Articles ,business.industry ,Liver Neoplasms ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,ctDNA ,hepatocellular carcinoma ,General Medicine ,Middle Aged ,medicine.disease ,tumor recurrence ,Circulating tumor DNA ,Hepatocellular carcinoma ,biomarker ,Molecular Medicine ,Biomarker (medicine) ,Female ,Neoplasm Recurrence, Local ,business ,Research Article - Abstract
We studied the value of circulating tumor DNA (ctDNA) in predicting early postoperative tumor recurrence and monitoring tumor burden in patients with hepatocellular carcinoma (HCC). Plasma‐free DNA, germline DNA, and tissue DNA were isolated from 41 patients with HCC. Serial ctDNAs were analyzed by next‐generation sequencing before and after operation. Whole‐exome sequencing was used to detect the DNA of HCC and adjacent tissues. In total, 47 gene mutations were identified in the ctDNA of the 41 patients analyzed before surgery. ctDNA was detected in 63.4% and 46% of the patient plasma pre‐ and postoperation, respectively. The preoperative ctDNA positivity rate was significantly lower in the nonrecurrence group than in the recurrence group. With a median follow‐up of 17.7 months, nine patients (22%) experienced tumor recurrence. ctDNA positivity at two time‐points was associated with significantly shorter recurrence‐free survival (RFS). Tumors with NRAS, NEF2L2, and MET mutations had significantly shorter times to recurrence than those without mutations and showed high recurrence prediction performance by machine learning. Multivariate analyses showed that the median variant allele frequency (VAF) of mutations in preoperative ctDNA was a strong independent predictor of RFS. ctDNA is a real‐time monitoring indicator that can accurately reflect tumor burden. The median VAF of baseline ctDNA is a strong independent predictor of RFS in individuals with HCC., Here, we studied the value of circulating tumor DNA (ctDNA), in combination with germline and tissue DNA by whole‐exome sequencing in patients withhepatocellular carcinoma (HCC). Our analysis demonstrated that ctDNA may serve as a real‐time monitoring indicator by accurately reflecting tumor burden, and as a strong independent predictor of recurrence‐free survival in HCC.
- Published
- 2021
43. Long noncoding RNA GIHCG promotes hepatocellular carcinoma progression through epigenetically regulating miR-200b/a/429
- Author
-
Sui, Cheng-jun, Zhou, Yan-ming, Shen, Wei-feng, Dai, Bing-hua, Lu, Jiong-jiong, Zhang, Min-feng, and Yang, Jia-mei
- Published
- 2016
- Full Text
- View/download PDF
44. Super-Selective Intra-Arterial Indocyanine Green Administration for Near-Infrared Fluorescence-Based Positive Staining of Hepatic Segmentation: A Feasibility Study
- Author
-
Chih-Chi Wang, Michele Diana, Wei-Feng Li, Yu-Fan Cheng, Yu-Yin Liu, Yueh-Wei Liu, Jacques Marescaux, Mahdi Al-Taher, and Chun-Yen Yu
- Subjects
Indocyanine Green ,Carcinoma, Hepatocellular ,Staining and Labeling ,business.industry ,Liver Neoplasms ,Near infrared fluorescence ,medicine.disease ,Resection ,chemistry.chemical_compound ,Image-guided surgery ,chemistry ,Hepatocellular carcinoma ,medicine ,Intra arterial ,Feasibility Studies ,Humans ,Laparoscopy ,Surgery ,Nuclear medicine ,business ,Positive staining ,Indocyanine green - Abstract
Background. Despite the increasing number of laparoscopic hepatic procedures for the resection of hepatocellular carcinoma (HCC), intraoperative tumor localization and demarcation remains challenging in comparison to open surgery. In this study, we evaluated the feasibility of positive liver segment staining through the super-selective intra-arterial indocyanine green (ICG) administration. Methods. Eight patients presenting with a single HCC underwent an interventional vascular procedure followed by laparoscopic surgery. A microcatheter was advanced into the hepatic artery branches perfusing the HCC followed by digital subtraction angiography and angiography computed tomography (angio-CT). Patients were then transferred to the operating room, and a laparoscopic hepatectomy was performed under ultrasound guidance. A 5 mL bolus of ICG with a concentration of .125 mg/mL was injected through the microcatheter, and a near-infrared laparoscope was used to detect the fluorescence signal to assess the correspondence between the fluorescence-based demarcation and the intraoperative ultrasound–based demarcation. Results. The duration for the angiography procedure was 32.7 +/− 5.3 min, and it took 242 +/− 118 min from the end of angiography procedure until the start of the surgical procedure. In all cases, the fluorescent liver segment was corresponding to the angio-CT findings. In 6/8 cases, fluorescence imaging was considered helpful in the identification of the resection line. In 3 patients, the resection line was changed according to the positively stained liver segment. Conclusion. We successfully demonstrated the feasibility of the super-selective intra-arterial ICG administration for fluorescence-based positive staining of hepatic segmentation during laparoscopic surgery for HCC (NCT04266548).
- Published
- 2021
45. Survival benefit of adjuvant transcatheter arterial chemoembolization for patients with hepatocellular carcinoma after anatomical hepatectomy.
- Author
-
Ye, Tai-Wei, Wang, Dong-Dong, Lu, Wen-Feng, Xie, Ya-Ming, Xu, Fei-Qi, Fu, Tian-Wei, Zhang, Kang-Jun, Liu, Si-Yu, Xie, Gui-Lin, Cheng, Jian, Jiang, Kai, Xiao, Zun-Qiang, Yao, Wei-Feng, Shen, Guo-Liang, Liu, Jun-Wei, Huang, Dong-Sheng, Zhang, Cheng-Wu, and Liang, Lei
- Subjects
CHEMOEMBOLIZATION ,HEPATECTOMY ,PROPENSITY score matching ,PROGNOSIS ,DISEASE relapse - Abstract
Although anatomical hepatectomy (AH) is widely used in the treatment of hepatocellular carcinoma (HCC), the prognosis is still unsatisfactory. The present study aimed to evaluate the survival benefit of adjuvant transcatheter arterial chemoembolization (TACE) for patients with HCC after AH. A total of 832 patients were stratified into with adjuvant TACE (443, 53.2%) and without adjuvant TACE group (389, 46.8%) AH. Propensity score matching (PSM) was performed to control for confounding factors, and multivariable Cox regression was performed to determine the independent risk factors. After PSM, the results showed that the adjuvant TACE group had better overall survival (OS) and recurrence-free survival (RFS). Among the patients with tumor recurrence, adjuvant TACE was associated with a high rate of early-stage tumor at recurrence, a lower recurrence rate around the frontal margin and extrahepatic metastases, and a higher rate of receiving curative treatment. Multivariable Cox regression analysis showed that adjuvant TACE was an independent prognostic factor for OS (HR 0.673, P = 0.001) and RFS (HR 0.650, P = 0.001). Patients with HCC after AH can benefit from postoperative adjuvant TACE. Therefore, adjuvant TACE should be considered for patients with a high risk of recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Causes of Death among Patients with Hepatocellular Carcinoma According to Chronic Liver Disease Etiology.
- Author
-
Yen, Yi-Hao, Kee, Kwong-Ming, Li, Wei-Feng, Liu, Yueh-Wei, Wang, Chih-Chi, Hu, Tsung-Hui, Tsai, Ming-Chao, Kuo, Yuan-Hung, and Lin, Chih-Yun
- Subjects
CAUSES of death ,HEPATITIS B ,LIVER tumors ,CHRONIC diseases ,ALCOHOL-induced disorders ,HEPATITIS C ,LIVER diseases ,RESEARCH funding ,HEPATOCELLULAR carcinoma - Abstract
Simple Summary: Hepatocellular carcinoma (HCC) is a highly aggressive and lethal form of liver cancer, and most patients with HCC die due to HCC-related causes. Although most patients die of HCC-related causes, non–HCC-related death represents a competing event among patients who engage in alcohol use and receive curative treatment and among patients 75 years and older in the hepatitis B virus and all-negative groups who receive curative treatments. All negative was defined as negative for hepatitis C virus, hepatitis B virus, and alcohol-related causes. The results of the current study underscore the importance of assessing and managing underlying comorbidities, especially among certain subgroups of patients with HCC. This study was conducted to determine whether the causes of death among patients with hepatocellular carcinoma (HCC) differ according to chronic liver disease (CLD) etiology. Between 2011 and 2020, 3977 patients who were newly diagnosed with HCC at our institution were enrolled in this study. We determined whether the cause of death was HCC-related and non-HCC-related. For patients with multiple CLD etiologies, etiology was classified using the following hierarchy: hepatitis C virus (HCV) > hepatitis B virus (HBV) > alcohol-related causes > all negative. All negative was defined as negative for HCV, HBV, and alcohol-related causes. Among 3977 patients, 1415 patients were classified as HCV-related, 1691 patients were HBV-related, 145 patients were alcohol-related, and 725 patients were all negative. HCC-related mortality was the leading cause of death, irrespective of etiology. Among patients who underwent curative treatment, HCC-related mortality was the leading cause of death for patients in the HCV, HBV, and all-negative groups, but not for patients in the alcohol-related group. Among patients 75 years and older who underwent curative treatment, HCC-related mortality was the leading cause of death in the HCV but not HBV or all-negative groups. In conclusion, although most patients with HCC die due to HCC-related causes, non-HCC-related mortality represents a competing event in certain patient subgroups. The current study results underscore the importance of assessing and managing underlying comorbidities, particularly among patients with HCC at risk of non-HCC-related mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
47. CD36+ cancer-associated fibroblasts provide immunosuppressive microenvironment for hepatocellular carcinoma via secretion of macrophage migration inhibitory factor.
- Author
-
Zhu, Gui-Qi, Tang, Zheng, Huang, Run, Qu, Wei-Feng, Fang, Yuan, Yang, Rui, Tao, Chen-Yang, Gao, Jun, Wu, Xiao-Ling, Sun, Hai-Xiang, Zhou, Yu-Fu, Song, Shu-Shu, Ding, Zhen-Bin, Dai, Zhi, Zhou, Jian, Ye, Dan, Wu, Duo-Jiao, Liu, Wei-Ren, Fan, Jia, and Shi, Ying-Hong
- Subjects
MACROPHAGE migration inhibitory factor ,HEPATOCELLULAR carcinoma ,FIBROBLASTS ,LIVER cells ,SECRETION ,PROGRAMMED cell death 1 receptors - Abstract
Hepatocellular carcinoma (HCC) is an immunotherapy-resistant malignancy characterized by high cellular heterogeneity. The diversity of cell types and the interplay between tumor and non-tumor cells remain to be clarified. Single cell RNA sequencing of human and mouse HCC tumors revealed heterogeneity of cancer-associated fibroblast (CAF). Cross-species analysis determined the prominent CD36
+ CAFs exhibited high-level lipid metabolism and expression of macrophage migration inhibitory factor (MIF). Lineage-tracing assays showed CD36+ CAFs were derived from hepatic stellate cells. Furthermore, CD36 mediated oxidized LDL uptake-dependent MIF expression via lipid peroxidation/p38/CEBPs axis in CD36+ CAFs, which recruited CD33+ myeloid-derived suppressor cells (MDSCs) in MIF- and CD74-dependent manner. Co-implantation of CD36+ CAFs with HCC cells promotes HCC progression in vivo. Finally, CD36 inhibitor synergizes with anti-PD-1 immunotherapy by restoring antitumor T-cell responses in HCC. Our work underscores the importance of elucidating the function of specific CAF subset in understanding the interplay between the tumor microenvironment and immune system. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
48. Stationary Trend in Elevated Serum Alpha-Fetoprotein Level in Hepatocellular Carcinoma Patients.
- Author
-
Yen, Yi-Hao, Kee, Kwong-Ming, Li, Wei-Feng, Liu, Yueh-Wei, Wang, Chih-Chi, Hu, Tsung-Hui, Tsai, Ming-Chao, and Lin, Chih-Yun
- Subjects
ALPHA fetoproteins ,HEPATITIS B ,HEPATITIS C ,CIRRHOSIS of the liver ,CANCER patients ,TUMOR classification ,LIVER diseases ,SEX distribution ,RESEARCH funding ,HEPATOCELLULAR carcinoma ,BILIRUBIN ,DISEASE complications - Abstract
Simple Summary: In this study, we demonstrated that overall 51.2% of patients with hepatocellular carcinoma (HCC) had elevated alpha-fetoprotein (AFP) levels. The proportion of patients with elevated AFP levels was stationary in the period from 2011 to 2020. The proportion of patients with Barcelona Clinic Liver Cancer classification (BCLC) stages 0–A HCC decreased from 2011 to 2020, whereas the proportion of patients with non-HBV- and non-HCV (NBNC)-HCC increased in the same period. Furthermore, the proportion of patients with early-stage HCC (i.e., BCLC stages 0–A) was lower for NBNC-HCC than for HBV- or HCV-related HCC. Advanced tumor stage, severe underlying liver disease, viral etiology, and female gender are associated with elevated AFP levels in HCC patients. A recent study from the US showed a decreasing trend in the elevated serum alpha-fetoprotein (AFP) level (i.e., ≥20 ng/mL) in hepatocellular carcinoma (HCC) patients at the time of diagnosis. Furthermore, advanced tumor stage and severe underlying liver disease were associated with elevated AFP levels. We aimed to evaluate this issue in an area endemic for hepatitis B virus (HBV). Between 2011 and 2020, 4031 patients were newly diagnosed with HCC at our institution. After excluding 54 patients with unknown AFP data, the remaining 3977 patients were enrolled in this study. Elevated AFP level was defined as ≥20 ng/mL. Overall, 51.2% of HCC patients had elevated AFP levels; this proportion remained stationary between 2011 and 2020 (51.8% vs. 51.1%). Multivariate analysis showed that female gender (odds ratio (OR) = 1.462; p < 0.001), tumor size per 10 mm increase (OR = 1.155; p < 0.001), multiple tumors (OR = 1.406; p < 0.001), Barcelona Clinic Liver Cancer stages B–D (OR = 1.247; p = 0.019), cirrhosis (OR = 1.288; p = 0.02), total bilirubin > 1.4 mg/dL (OR = 1.218; p = 0.030), and HBV- or hepatitis C virus (HCV)-positive status (OR = 1.720; p < 0.001) were associated with elevated AFP levels. In conclusion, a stationary trend in elevated serum AFP level in HCC patients has been noted in the past 10 years. Advanced tumor stage, severe underlying liver disease, viral etiology, and female gender are associated with elevated AFP levels in HCC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. Alpha-Fetoprotein Combined with Radiographic Tumor Burden Score to Predict Overall Survival after Liver Resection in Hepatocellular Carcinoma.
- Author
-
Yen, Yi-Hao, Liu, Yueh-Wei, Li, Wei-Feng, Wang, Chih-Chi, Yong, Chee-Chien, Lin, Chih-Che, and Lin, Chih-Yun
- Subjects
LIVER surgery ,ALPHA fetoproteins ,REFERENCE values ,CONFIDENCE intervals ,MULTIVARIATE analysis ,CANCER patients ,DESCRIPTIVE statistics ,RESEARCH funding ,HEPATOCELLULAR carcinoma - Abstract
Simple Summary: The tumor burden score (TBS) is calculated using the Pythagorean theorem based on the largest tumor size and tumor number (α
2 + β2 = γ2 , where α is the largest tumor size, β is the tumor number, and γ is the TBS). Patients who underwent liver resection (LR) for Barcelona Clinic Liver Cancer stage 0, A, or B hepatocellular carcinoma (HCC) between 2011 and 2018 were enrolled. Among 743 patients, 193 (26.0%) patients had a low TBS (<2.6), 474 (63.8%) had a moderate TBS (2.6–7.9), and 75 (10.1%) had a high TBS (>7.9). Combining radiographic TBS and alpha-fetoprotein levels could stratify overall survival among HCC patients after LR. We evaluated whether combining the radiographic tumor burden score (TBS) and alpha-fetoprotein (AFP) level could be used to stratify overall survival (OS) among hepatocellular carcinoma (HCC) patients after liver resection (LR). Patients who underwent LR for Barcelona Clinic Liver Cancer stage 0, A, or B HCC between 2011 and 2018 were enrolled. TBS scores were calculated using the following equation: TBS2 = (largest tumor size (in cm))2 + (tumor number)2 . Among 743 patients, 193 (26.0%) patients had a low TBS (<2.6), 474 (63.8%) had a moderate TBS (2.6–7.9), and 75 (10.1%) had a high TBS (>7.9). Those with a TBS ≤ 7.9 and AFP < 400 ng/mL had a significantly better OS than those with a TBS > 7.9 and an AFP < 400 ng/mL (p = 0.003) or ≥ 400 ng/mL (p < 0.001). A multivariate analysis using TBS ≤ 7.9 and AFP < 400 ng/mL as the reference values showed that a TBS > 7.9 and an AFP < 400 ng/mL (hazard ratio (HR): 2.063; 95% confidence interval [CI]: 1.175–3.623; p = 0.012) or ≥ 400 ng/mL (HR: 6.570; 95% CI: 3.684–11.719; p < 0.001) were independent predictors of OS. In conclusion, combining radiographic TBSs and AFP levels could stratify OS among HCC patients undergoing LR. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
50. Microscopic vascular invasion may not be associated with survival of patients undergoing resection for solitary hepatoma of ≤ 2 cm.
- Author
-
Li, Wei-Feng, Liu, Yueh-Wei, Wang, Chih-Chi, Yong, Chee-Chien, Lin, Chih-Che, and Yen, Yi-Hao
- Subjects
- *
OVERALL survival , *HEPATOCELLULAR carcinoma , *MULTIVARIATE analysis , *UNIVARIATE analysis , *DISEASE relapse - Abstract
Background/objective: To determine the impact of microvascular invasion (MVI) on outcome in patients with solitary hepatocellular carcinoma (HCC) of ≤ 2 cm undergoing liver resection (LR). Methods: This retrospective study enrolled consecutive patients between 2007–2019 with newly diagnosed solitary HCC ≤ 2 cm who were undergoing LR at our institution. Overall survival (OS) and recurrent-free survival (RFS) were compared between patients with or without MVI. Results: Of the 229 patients included in this study, 71 had MVI. The median follow-up period was 28.8 months (interquartile range: 13.5–70.1). Although the 90-day mortality rate was 0, 18 deaths occurred during the study, and the 5-year survival rate was 87.1%. Tumor recurrence occurred in 45 cases, and 5-year RFS was 71.9%. The presence or absence of MVI did not significantly affect the OS and RFS rates (log rank test, p = 0.10 and 0.38, respectively). In univariate and multivariate analysis, the presence of MVI was not associated with OS and RFS. Conclusion: The presence of MVI was not associated with OS and RFS in patients with solitary HCC ≤ 2 cm who underwent LR in this cohort. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.